Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
  • C07B59/002—Heterocyclic compounds
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

• R 1 is -CH 3 , -CD 3 , -CHD 2 , or -CH 2 D;
• R 2 is hydrogen or -D
• R 3 is hydrogen or -D
• R 4 is hydrogen, -CH 2 CH 3 ; -CD 2 CD 3 ; -CD 2 CH 3 ; -CH 2 CD 3 ; -CDHCH 3 ; -CH 2 CDH 2 ; -CH 2 CD 2 H; - CD 2 CDH 2 ; -CD 2 CD 2 H; -CDHCD 3 ; -CDHCDH 2 ; or -CDHCD 2 H;
• R 5 is hydrogen, -CH 2 CH 3 ; -CD 2 CD 3 ; -CD 2 CH 3 ; -CH 2 CD 3 ; -CDHCH 3 ; -CH 2 CDH 2 ; -CH 2 CD 2 H; - CD 2 CDH 2 ; -CD 2 CD 2 H; -CDHCD 3 ; -CDHCDH 2 ; or -CDHCD 2 H; and wherein at least one of R 1 , R 2 , R 3 , R 4 , or R 5 , comprises at least one deuterium atom.
• a compound or a pharmaceutically acceptable salt, co crystal or solvate thereof that is:
• a compound or a pharmaceutically acceptable salt, co crystal or solvate thereof that is:
• a compound or a pharmaceutically acceptable salt, co crystal or solvate thereof that is:
• a compound or a pharmaceutically acceptable salt, co crystal or solvate thereof that is:
• a compound or a pharmaceutically acceptable salt, co crystal or solvate thereof that is:
• a compound or a pharmaceutically acceptable salt, co crystal or solvate thereof that is:
• a compound or a pharmaceutically acceptable salt, co crystal or solvate thereof that is:
• a compound or a pharmaceutically acceptable salt, co crystal or solvate thereof that is:
• a compound or a pharmaceutically acceptable salt, co crystal or solvate thereof that is:
• a compound or a pharmaceutically acceptable salt, co crystal or solvate thereof that is:
• the positions represented as D have deuterium enrichment of at least 98%. In some embodiments, in any one of the compounds disclosed herein, or in pharmaceutically acceptable salts, co-crystals or solvates thereof, the positions represented as D have deuterium enrichment of at least 90%. In some embodiments, in any one of the compounds disclosed herein, or in pharmaceutically acceptable salts, co-crystals or solvates thereof, the positions represented as D have deuterium enrichment of at least 50%. In some embodiments, in any one of the compounds disclosed herein, or in pharmaceutically acceptable salts, co-crystals or solvates thereof, the positions represented as D have deuterium enrichment of at least 10%.
• a pharmaceutical composition comprising any one of the compounds disclosed herein, or a pharmaceutically acceptable salt, co-crystal or solvate thereof, and a pharmaceutically acceptable carrier.
• a method of treating Parkinson’s disease or a movement disorder associated with Parkinson’s disease in a subject in need thereof comprising administering to the subject any one of the compounds disclosed herein or a pharmaceutical composition disclosed herein.
• a method of treating Parkinson’s disease or a movement disorder associated with Parkinson’s disease in a subject in need thereof comprising administering to the subject a therapeutically effective combination of (a) any one of the compounds disclosed herein or a pharmaceutical composition disclosed herein, and (b) an additional therapeutic agent.
• the additional therapeutic agent is a dopamine precursor.
• the dopamine precursor is levodopa.
• the additional therapeutic agent is a dopamine agonist.
• the dopamine agonist is pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine, or a combination thereof.
• the additional therapeutic agent is a dopamine agonist comprising pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine, or a combination thereof.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor.
• the COMT inhibitor is entacapone or tolcapone.
• the COMT inhibitor is entacapone, tolcapone, or opicapone.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor comprising entacapone, tolcapone, or opicapone.
• the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor.
• the MAOB inhibitor is selegiline or rasagiline.
• the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor comprising selegiline or rasagiline.
• the additional therapeutic agent is a dopa decarboxylase inhibitor.
• the dopa decarboxylase inhibitor is carbidopa or benserazide.
• the additional therapeutic agent is a dopa decarboxylase inhibitor comprising carbidopa or benserazide.
• the movement disorder to be treated is dyskinesia.
• the dyskinesia is levodopa-induced dyskinesia (LID), diphasic dyskinesia, or peak-dose dyskinesia.
• the movement disorder to be treated is dystonia.
• the dystonia is generalized dystonia, focal dystonia, segmental dystonia, or acute dystonia.
• the movement disorder to be treated is akathisia.
• the akathisia is acute akathisia, chronic akathisia, pseudoakathisia, or withdrawal akathisia.
• the subject to be treated is diagnosed with Parkinson’s disease.
• a pharmaceutical combination for use for the treatment or prevention of Parkinson’s disease or a movement disorder associated with Parkinson’s disease in a subject in need thereof comprising: a therapeutic combination of (a) any of the compounds disclosed herein or any of the pharmaceutical compositions disclosed herein; and (b) an additional therapeutic agent for treating Parkinson’s disease.
• the additional therapeutic agent is a dopamine precursor.
• the dopamine precursor is levodopa.
• the additional therapeutic agent is a dopamine agonist.
• the dopamine agonist is pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a dopamine agonist comprising pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor.
• the COMT inhibitor is entacapone or tolcapone.
• the COMT inhibitor is entacapone, tolcapone, or opicapone.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor. In some embodiments comprising entacapone, tolcapone, or opicapone.
• the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor. In some embodiments, the MAOB inhibitor is selegiline or rasagiline. In some embodiments, the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor comprising selegiline or rasagiline. In some embodiments, the additional therapeutic agent is a dopa decarboxylase inhibitor.
• the dopa decarboxylase inhibitor is carbidopa or benserazide.
• the additional therapeutic agent is a dopa decarboxylase inhibitor comprising carbidopa or benserazide.
• the movement disorder is dyskinesia.
• the dyskinesia is levodopa-induced dyskinesia (LID), diphasic dyskinesia, or peak-dose dyskinesia.
• the movement disorder is dystonia.
• the dystonia is generalized dystonia, focal dystonia, segmental dystonia, or acute dystonia.
• the movement disorder is akathisia.
• the akathisia is acute akathisia, chronic akathisia, pseudoakathisia, or withdrawal akathisia.
• the subject is diagnosed with Parkinson’s disease.
• FIG. 1 shows a plasma concentration (ng/mL, linear scale) time profde of male Sprague Dawley rats following oral administration of Trapidil (diamond), Example 3-1 (square), 3-2 (triangle) and 3-3 (circle).
• FIG. 2 shows the same results as FIG. 1 in logarithmic scale.
• FIG. 3 shows a plasma concentration (ng/mL, linear scale) time profde of male Sprague Dawley rats following intravenous administration of Trapidil (diamond), Example 3-1 (square), 3-2 (triangle) and 3- 3 (circle).
• FIG. 4 shows the same results as FIG. 3 in logarithmic scale.
• Trapidil derivatives for treating Parkinson’s disease and movement disorders associated with Parkinson’s disease in a subject in need thereof.
• the Trapidil derivative is isotopically-labelled.
• the Trapidil-derivative is deuterated.
• the movement disorder is an adverse drug reaction to a therapeutic agent used to treat Parkinson’s disease.
• the Trapidil derivatives of the present disclosure are administered to a subject in need alone, or in combination with an additional therapeutic agent.
• the additional therapeutic agent is a dopamine precursor, dopamine agonist, Catechol O-methyl transferase (COMT) inhibitor, monoamine oxidase B (MAOB) inhibitor, or dopa decarboxylase inhibitor.
• CCT Catechol O-methyl transferase
• MAOB monoamine oxidase B
• Parkinson’s disease is the second most common neurodegenerative disorder. Parkinson’s disease is associated with severe motor, cognitive, and emotional disturbances. Although the mechanism(s) underlying Parkinson’s disease neurodegeneration remains unclear, the loss of dopaminergic terminals in the neostriatum and neuronal cell bodies underlie the motor symptoms. Parkinson’s disease has pharmacological treatments primarily for motor symptoms and typically increase activation of the two dopamine receptors type: Dopamine 1 receptors (Dl, D5) and Dopamine 2 receptors (D2-D4). Dopamine 1 receptors (DIR) are located on striatonigral neurons in the striatum and are activated by dopamine.
• DIR Dopamine 1 receptors
• Dopamine 2 receptors are located on striatopallidal neurons in the striatum and are inhibited by dopamine. Pharmacological activation of DIR in Parkinson’s disease models increases expression of several transcripts including FOS, FOSB, JU B, ARC, and EGR4 which are implicated in the induction of dyskinesia.
• Levodopa is the gold standard for treatment of Parkinson’s disease and movement disorders associated with Parkinson’s disease. Levodopa utilization over time by Parkinson’s disease patients leads to motor complications, which include loss of therapeutic efficacy of Levodopa and Levodopa-induced dyskinesia. Further, current adjuvants to levodopa (such as COMT inhibitors, MAOB inhibitors, D2 agonists) exacerbate dyskinesia. Thus, there exists a need for therapeutic agents with fewer side effects that do not cause motor complications in Parkinson’s disease patients.
• ⁇ Disclosed herein, in certain embodiments, are combination therapies of Trapidil derivatives and an additional therapeutic agent.
• the additional therapeutic agent is levodopa and/or carbidopa.
• the Trapidil derivatives of the present disclosure are, in some embodiments, isotopically-labelled Trapidil derivatives. In some embodiments, the isotopically-labelled Trapidil derivative is adeuterated Trapidil compound.
• the method comprises further administering an additional therapeutic agent to the subject.
• the additional therapeutic agent is levodopa and/or carbidopa.
• the levodopa and/or carbidopa is administered to the subject before, after, or simultaneous with the isotopically-labelled Trapidil derivative.
• the animal body expresses various enzymes, such as the cytochrome P 450 enzymes or CYPs, esterases, proteases, reductases, dehydrogenases, and monoamine oxidases, to react with and convert these foreign substances to more polar intermediates or metabolites for renal excretion.
• enzymes such as the cytochrome P 450 enzymes or CYPs, esterases, proteases, reductases, dehydrogenases, and monoamine oxidases.
• Some of the most common metabolic reactions of pharmaceutical compounds involve the oxidation of a carbon-hydrogen (C-H) bond to either a carbon-oxygen (C-O) or carbon-carbon (C-C) p-bond.
• the resultant metabolites may be stable or unstable under physiological conditions, and can have substantially different pharmacokinetic, pharmacodynamic, and acute and long-term toxicity profiles relative to the parent compounds. For most drugs, such oxidations are generally rapid and ultimately lead to administration of multiple or high daily doses.
• the Arrhenius equation states that the fraction of molecules that have enough energy to overcome an energy barrier, that is, those with energy at least equal to the activation energy, depends exponentially on the ratio of the activation energy to thermal energy (RT), the average amount of thermal energy that molecules possess at a certain temperature.
• the transition state in a reaction is a short lived state (on the order of 10 14 sec) along the reaction pathway during which the original bonds have stretched to their limit.
• the activation energy E act for a reaction is the energy required to reach the transition state of that reaction. Reactions that involve multiple steps will necessarily have a number of transition states, and in these instances, the activation energy for the reaction is equal to the energy difference between the reactants and the most unstable transition state. Once the transition state is reached, the molecules can either revert, thus reforming the original reactants, or new bonds form giving rise to the products. This dichotomy is possible because both pathways, forward and reverse, result in the release of energy.
• a catalyst facilitates a reaction process by lowering the activation energy leading to a transition state. Enzymes are examples of biological catalysts that reduce the energy necessary to achieve a particular transition state.
• a carbon-hydrogen bond is by nature a covalent chemical bond. Such a bond forms when two atoms of similar electronegativity share some of their valence electrons, thereby creating a force that holds the atoms together. This force or bond strength can be quantified and is expressed in units of energy, and as such, covalent bonds between various atoms can be classified according to how much energy must be applied to the bond in order to break the bond or separate the two atoms.
• the bond strength is directly proportional to the absolute value of the ground-state vibrational energy of the bond.
• This vibrational energy which is also known as the zero-point vibrational energy, depends on the mass of the atoms that form the bond.
• the absolute value of the zero-point vibrational energy increases as the mass of one or both of the atoms making the bond increases. Since deuterium (D) has twice the mass of hydrogen (H), it follows that a C-D bond is stronger than the corresponding C-H bond.
• Compounds with C-D bonds are frequently indefinitely stable in EfiO, and have been widely used for isotopic studies. If a C-H bond is broken during a rate -determining step in a chemical reaction (i.e.
• DKIE Deuterium Kinetic Isotope Effect
• High DKIE values may be due in part to a phenomenon known as tunneling, which is a consequence of the uncertainty principle. Tunneling is ascribed to the small size of a hydrogen atom, and occurs because transition states involving a proton can sometimes form in the absence of the required activation energy. A deuterium is larger and statistically has a much lower probability of undergoing this phenomenon. Substitution of tritium for hydrogen results in yet a stronger bond than deuterium and gives numerically larger isotope effects.
• deuterium is a stable and non-radioactive isotope of hydrogen. It was the first isotope to be separated from its element in pure form and has twice the mass of hydrogen, and makes up about 0.02% of the total mass of hydrogen (in this usage meaning all hydrogen isotopes) on earth.
• deuterium oxide (D2O or “heavy water”) is formed. D2O looks and tastes like H2O, but has different physical properties. It boils at 101.41 °C and freezes at 3.79 °C. Its heat capacity, heat of fusion, heat of vaporization, and entropy are all higher than H2O. It is more viscous and has different solubilizing properties than H2O.
• the animals also become very aggressive; males becoming almost unmanageable. When about 30%, of the body water has been replaced with D2O, the animals refuse to eat and become comatose. Their body weight drops sharply and their metabolic rates drop far below normal, with death occurring at about 30 to about 35% replacement with D2O. The effects are reversible unless more than thirty percent of the previous body weight has been lost due to D2O. Studies have also shown that the use of D2O can delay the growth of cancer cells and enhance the cytotoxicity of certain antineoplastic agents.
• Tritium (T) is a radioactive isotope of hydrogen, used in research, fusion reactors, neutron generators and radiopharmaceuticals. Mixing tritium with a phosphor provides a continuous light source, a technique that is commonly used in wristwatches, compasses, rifle sights and exit signs. It was discovered by Rutherford, Oliphant and Harteck in 1934, and is produced naturally in the upper atmosphere when cosmic rays react with 3 ⁇ 4 molecules. Tritium is a hydrogen atom that has 2 neutrons in the nucleus and has an atomic weight close to 3. It occurs naturally in the environment in very low concentrations, most commonly found as T2O, a colorless and odorless liquid.
• PK pharmacokinetics
• PD pharmacodynamics
• toxicity profiles have been demonstrated previously with some classes of drugs.
• DKIE was used to decrease the hepatotoxicity of halothane by presumably limiting the production of reactive species such as trifluoroacetyl chloride.
• this method may not be applicable to all drug classes.
• deuterium incorporation can lead to metabolic switching which may even give rise to an oxidative intermediate with a faster off-rate from an activating Phase I enzyme (e.g., cytochrome P4503A4).
• the carbon-hydrogen bonds of Trapidil contain a naturally occurring distribution of hydrogen isotopes, namely 3 ⁇ 4 or protium (about 99.9844%), 2 H or deuterium (about 0.0156%), and 3 H or tritium (in the range between about 0.5 and 67 tritium atoms per 10 18 protium atoms).
• Increased levels of deuterium incorporation produce a detectable Kinetic Isotope Effect (KIE) that could affect the pharmacokinetic, pharmacologic and/or toxicologic parameters in comparison to compounds having naturally occurring levels of deuterium.
• KIE Kinetic Isotope Effect
• R 1 is -CH 3 , -CD 3 , -CHD 2 , or -CH 2 D;
• R 2 is hydrogen or -D
• R 3 is hydrogen or -D
• R 4 is hydrogen; -CH 2 CH 3 ; -CD 2 CD 3 ; -CD 2 CH 3 ; -CH 2 CD 3 ; -CDHCH 3 ; -CH 2 CDH 2 ; -CH 2 CD 2 H; - CD 2 CDH 2 ; -CD 2 CD 2 H; -CDHCD 3 ; -CDHCDH 2 ; or -CDHCD 2 H;
• R 5 is hydrogen; -CH 2 CH 3 ; -CD 2 CD 3 ; -CD 2 CH 3 ; -CH 2 CD 3 ; -CDHCH 3 ; -CH 2 CDH 2 ; -CH 2 CD 2 H; - CD 2 CDH 2 ; -CD 2 CD 2 H; -CDHCD 3 ; -CDHCDH 2 ; -CDHCD 2 H; wherein at least one of R 1 , R 2 , R 3 , R 4 , or R 5 comprises at least one deuterium atom.
• R 1 is -CH 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 1 is -CD 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 1 is -CHD 2 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 1 is -CH 2 D.
• R 2 is hydrogen. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 2 is -D.
• R 3 is hydrogen. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, co-crystal or solvate thereof, R 3 is -D.
• R 4 is hydrogen. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 4 is -CH 2 CH 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 4 is - CD 2 CD 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, R 4 is -CD 2 CH 3 .
• R 4 is -CH 2 CD 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 4 is - CDHCH 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, R 4 is -CH 2 CDH 2 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 4 is -CH 2 CD 2 H.
• R 4 is - CD 2 CDH 2 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, R 4 is -CD 2 CD 2 H. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 4 is -CDHCD 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 4 is - CDHCDH 2 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, R 4 is -CDHCD 2 H.
• R 5 is -CH 2 CH 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 5 is -CD 2 CD 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 5 is - CD 2 CH 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, R 5 is -CH 2 CD 3 .
• R 5 is -CDHCH 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 5 is - CH 2 CDH 2 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, R 5 is -CH 2 CD 2 H. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 5 is -CD 2 CDH 2 .
• R 5 is - CD 2 CD 2 H. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, R 5 is -CDHCD 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 5 is -CDHCDH 2 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 5 is - CDHCD2H. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, any position represented as D has deuterium enrichment of at least 98%.
• any position represented as D has deuterium enrichment of at least 90%. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, any position represented as D has deuterium enrichment of at least 80%.
• any position represented as D has deuterium enrichment of at least 70%. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, any position represented as D has deuterium enrichment of at least 60%.
• any position represented as D has deuterium enrichment of at least 50%. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, any position represented as D has deuterium enrichment of at least 40%.
• any position represented as D has deuterium enrichment of at least 30%. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, any position represented as D has deuterium enrichment of at least 20%.
• any position represented as D has deuterium enrichment of at least 10%. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, any position represented as D has deuterium enrichment of at least 5%. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, any position represented as D has deuterium enrichment of at least 1%.
• the Trapidil derivative disclosed herein i In some embodiments, the Trapidil derivative disclosed herein
• the Trapidil derivative disclosed herein [0060] In some embodiments, the Trapidil derivative disclosed herein [0061] In some embodiments, the Trapidil derivative disclosed herein i
• the Trapidil derivative disclosed herein i In some embodiments, the Trapidil derivative disclosed herein
• the Trapidil derivative disclosed herein [0075] In some embodiments, the Trapidil derivative disclosed herein
• the Trapidil derivative disclosed herein is.
• the deuterated Trapidil derivatives provided herein maintain the beneficial aspects of the corresponding non-isotopically enriched molecules while increasing the half-life (T1 / 2), lowering the maximum plasma concentration (Cma x ) of the minimum efficacious dose (MED), lowering the efficacious dose and thus decreasing the non-mechanism-related toxicity, and/or lowering the probability of drug-drug interactions.
• the deuterated Trapidil derivatives cause changes in the pharmacological activity of drugs.
• Isotopic hydrogen can be introduced into a compound of Formula (I) as provided herein by synthetic techniques that employ deuterated reagents, whereby incorporation rates are pre-determined; and/or by exchange techniques, wherein incorporation rates are determined by equilibrium conditions, and may be highly variable depending on the reaction conditions. Synthetic techniques, where tritium or deuterium is directly and specifically inserted by tritiated or deuterated reagents of known isotopic content, may yield high tritium or deuterium abundance, but can be limited by the chemistry required. In addition, the molecule being labelled may be changed, depending upon the severity of the synthetic reaction employed.
• Trapidil derivatives provided herein can be prepared by any suitable methods.
• Deuterium can be incorporated to different positions synthetically by using appropriate deuterated intermediates. These deuterated intermediates are either commercially available, or can be prepared by any suitable methods or following procedures similar to those described in the Journal of Organic Chemistry, 48(20), 3458-3464, 1983 or Journal of Chemical and Engineering Data, 55(5), 2048-2054; 2010 and routine modifications thereof.
• the Trapidil derivatives described herein exist as their pharmaceutically acceptable salts.
• the methods disclosed herein include methods of treating Parkinson’s disease and movement disorders associated with Parkinson’s disease comprising administering such pharmaceutically acceptable salts.
• the methods disclosed herein include methods of treating Parkinson’s disease and movement disorders associated with Parkinson’s disease comprising administering such pharmaceutically acceptable salts as pharmaceutical compositions.
• the movement disorder is dyskinesia.
• the dyskinesia is levodopa- induced dyskinesia (LID), diphasic dyskinesia, or peak-dose dyskinesia.
• the movement disorder is dystonia.
• the dystonia is generalized dystonia, focal dystonia, segmental dystonia, or acute dystonia.
• the movement disorder is akathisia.
• the akathisia is acute akathisia, chronic akathisia, pseudoakathisia, or withdrawal akathisia.
• the Trapidil derivatives described herein possess acidic or basic groups and therefore react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
• these salts are prepared in situ during the final isolation and purification of the Trapidil derivatives disclosed herein, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
• Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the Trapidil derivatives described herein with a mineral, organic acid or inorganic base, such salts including, acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyn-l,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, fiimarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-l,6
• the Trapidil derivatives described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the Trapidil derivative with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methane sulfonic acid, ethane
• those Trapidil derivatives described herein which comprise a free acid group react with a suitable base, such as the hydroxide, carbonate, bicarbonate, sulfate, of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine.
• a suitable base such as the hydroxide, carbonate, bicarbonate, sulfate, of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine.
• Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like.
• bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N + (C I-4 alkyl)4, and the like.
• Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. It should be understood that the Trapidil derivatives described herein also include the quatemization of any basic nitrogen-containing groups they contain. In some embodiments, water or oil-soluble or dispersible products are obtained by such quatemization.
• the Trapidil derivatives described herein exist as solvates.
• methods of treating Parkinson’s disease and movement disorders associated with Parkinson’s disease comprising administering such solvates.
• methods of treating Parkinson’s disease and movement disorders associated with Parkinson’s disease comprising administering such solvates as pharmaceutical compositions.
• the movement disorder is dyskinesia.
• the dyskinesia is levodopa-induced dyskinesia (LID), diphasic dyskinesia, or peak-dose dyskinesia.
• the movement disorder is dystonia.
• the dystonia is generalized dystonia, focal dystonia, segmental dystonia, or acute dystonia.
• the movement disorder is akathisia.
• the akathisia is acute akathisia, chronic akathisia, pseudoakathisia, or withdrawal akathisia.
• Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and, in some embodiments, are formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol.
• Solvates of the Trapidil derivatives described herein can be conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the Trapidil derivatives described herein can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents including, but not limited to, dioxane, tetrahydrofuran or methanol.
• the Trapidil derivatives provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the Trapidil derivatives and methods provided herein.
• compositions comprising a Trapidil derivative disclosed herein, in a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof; and one or more pharmaceutically acceptable excipients or carriers.
• the pharmaceutical compositions provided herein may be provided in unit-dosage forms or multiple-dosage forms.
• Unit-dosage forms refer to physically discrete units suitable for administration to human and animal subjects and packaged individually as is known in the art.
• Each unit- dose contains a predetermined quantity of the active ingredient(s) sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carriers or excipients.
• unit- dosage forms include ampules, syringes, and individually packaged tablets and capsules.
• Unit-dosage forms may be administered in fractions or multiples thereof.
• a multiple-dosage form is a plurality of identical unit- dosage forms packaged in a single container to be administered in segregated unit-dosage form. Examples of multiple-dosage forms include vials, bottles of tablets or capsules, or bottles of pints or gallons.
• compositions provided herein may be administered at once, or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the patient being treated, and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted overtime according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations.
• the administration of the Trapidil derivatives may be administered chronically, that is, for an extended period of time, including throughout the duration of a patient’s life in order to ameliorate or otherwise control or limit the symptoms of the Parkinson’s disease or movement disorder associated with Parkinson’s disease.
• the pharmaceutical compositions described herein are administered for therapeutic applications.
• the pharmaceutical composition is administered once per day, twice per day, three times per day or more.
• the pharmaceutical composition is administered daily, every day, every alternate day, five days a week, once a week, every other week, two weeks per month, three weeks per month, once a month, twice a month, three times per month, or more.
• the pharmaceutical composition is administered for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 18 months, 2 years, 3 years, or more.
• the administration of the composition is given continuously; alternatively, the dose of the composition being administered is temporarily reduced or temporarily suspended for a certain length of time (i.e., a “drug holiday”).
• the length of the drug holiday varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days.
• the dose reduction during a drug holiday is from 10%-100%, including, by way of example only,
• a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, can be reduced, as a function of the symptoms, to a level at which the improved Parkinson’s disease or movement disorder associated with Parkinson’s disease is retained.
• the amount of a Trapidil derivative administered to treat the Parkinson’s disease or movement disorder associated with Parkinson’s disease varies depending upon factors such as the particular Trapidil derivative, the severity of the disease, the identity (e.g., weight) of the subject or host in need of treatment, but nevertheless is routinely determined in a suitable method according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, and the subject or host being treated.
• the desired dose is conveniently presented in a single dose or as divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, for example as two, three, four or more sub-doses per day.
• toxicity and therapeutic efficacy of such therapeutic regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
• the dose ratio between the toxic and therapeutic effects is the therapeutic index and it is expressed as the ratio between LD50 and ED50.
• Trapidil derivatives exhibiting high therapeutic indices are preferred.
• the data obtained from cell culture assays and animal studies are used in formulating a range of dosage for use in human.
• the dosage of such Trapidil derivatives lies preferably within a range of circulating concentrations that include the ED50 with minimal toxicity. The dosage varies within this range depending upon the dosage form employed and the route of administration utilized.
• the Trapidil derivative disclosed herein is administered in a single dose. In some embodiments, the Trapidil derivative disclosed herein is administered in several doses, e.g., in 2, 3, 4, 5, 6, or more doses per day. In some embodiments, the Trapidil derivative disclosed herein is administered intravenously or subcutaneously. In such instances, the intravenous or subcutaneous administration dose ranges from about lmg/kg body weight to about lOmg/kg body weight, from about 2mg/kg body weight to about lOmg/kg body weight, or from about 4mg/kg body weight to about 8mg/kg body weight.
• compositions are formulated in a conventional manner using one or more physiologically acceptable carriers including excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients are used as suitable and as understood in the art. A summary of pharmaceutical compositions described herein are found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington ’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A.
• a pharmaceutical composition refers to a mixture of a Trapidil derivative disclosed herein, with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
• the pharmaceutical composition or combination facilitates administration of the compound to an organism.
• therapeutically effective amounts of a Trapidil derivative disclosed herein are administered in a pharmaceutical composition to a mammal having Parkinson’s disease or movement disorders associated with Parkinson’s disease.
• the mammal is a human.
• a therapeutically effective amount can vary widely depending on the severity of the Parkinson’s disease or movement disorders associated with Parkinson’s disease, the age and relative health of the subject, the potency of the Trapidil derivative used and other factors.
• Methods of Use [00105] Disclosed herein, in certain embodiments, are methods of treating Parkinson’s disease and movement disorders associated with Parkinson’s disease in a subject in need thereof, comprising administering to the subject a Trapidil derivative of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof: Formula (I); wherein
• R 1 is -CH 3 , -CD 3 , -CHD 2 , or -CH 2 D;
• R 2 is hydrogen or -D
• R 3 is hydrogen or -D
• R 4 is hydrogen; -CH 2 CH 3 ; -CD 2 CD 3 ; -CD 2 CH 3 ; -CH 2 CD 3 ; -CDHCH 3 ; -CH 2 CDH 2 ; -CH 2 CD 2 H; - CD 2 CDH 2 ; -CD 2 CD 2 H; -CDHCD 3 ; -CDHCDH 2 ; or -CDHCD 2 H;
• R 5 is hydrogen; -CH 2 CH 3 ; -CD 2 CD 3 ; -CD 2 CH 3 ; -CH 2 CD 3 ; -CDHCH 3 ; -CH 2 CDH 2 ; -CH 2 CD 2 H; - CD 2 CDH 2 ; -CD 2 CD 2 H; -CDHCD 3 ; -CDHCDH 2 ; or -CDHCD 2 H; wherein at least one of R 1 , R 2 , R 3 , R 4 , or R 5 , comprises at least one deuterium atom.
• R 1 is -CH 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 1 is -CD 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 1 is -CHD 2 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 1 is -CH 2 D.
• R 2 is hydrogen. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 2 is -D.
• R 3 is hydrogen. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, co-crystal or solvate thereof, R 3 is -D. [00109] In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, R 4 is hydrogen. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 4 is -CH 2 CH 3 .
• R 4 is - CD 2 CD 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, R 4 is -CD 2 CH 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 4 is -CH 2 CD 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 4 is - CDHCH 3 .
• R 4 is -CH 2 CDH 2 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 4 is -CH 2 CD 2 H. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 4 is - CD 2 CDH 2 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, R 4 is -CD 2 CD 2 H.
• R 4 is -CDHCD 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 4 is - CDHCDFh. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, R 4 is -CDHCD 2 H.
• R 5 is -CH 2 CH 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 5 is -CD 2 CD 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 5 is - CD 2 CH 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, R 5 is -CH 2 CD 3 .
• R 5 is -CDHCH 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 5 is - CH 2 CDH 2 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, R 5 is -CH 2 CD 2 H. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 5 is -CD 2 CDH 2 .
• R 5 is - CD 2 CD 2 H. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, R 5 is -CDHCD 3 . In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 5 is -CDHCDFh. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal or solvate thereof, R 5 is - CDHCD 2 H. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt, co crystal or solvate thereof, any position represented as D has deuterium enrichment of at least 98%.
• the methods further comprise treating the subject with an additional therapeutic agent.
• the methods comprise administering the Trapidil derivative disclosed herein and the additional therapeutic agent separately or together.
• the additional therapeutic agent is a dopamine precursor. In some embodiments, the dopamine precursor is levodopa. In some embodiments, the additional therapeutic agent is a dopamine agonist. In some embodiments, the dopamine agonist is pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine. In some embodiments, the additional therapeutic agent is a dopamine agonist comprising pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor.
• the COMT inhibitor is entacapone or tolcapone.
• the COMT inhibitor is entacapone, tolcapone, or opicapone.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor comprising entacapone, tolcapone, or opicapone.
• the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor.
• the MAOB inhibitor is selegiline or rasagiline.
• the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor comprising selegiline or rasagiline.
• MAOB monoamine oxidase B
• the additional therapeutic agent is a dopa decarboxylase inhibitor.
• the dopa decarboxylase inhibitor is carbidopa or benserazide.
• the additional therapeutic agent is a dopa decarboxylase inhibitor comprising carbidopa or benserazide.
• a movement disorder associated with Parkinson’s disease is a movement disorder resulting from the treatment of Parkinson’s disease.
• the movement disorder is an adverse drug reaction or negative side effect of a drug used to treat Parkinson’s disease, such as levodopa.
• the subject to be treated with the Trapidil derivatives described herein is diagnosed with or suspected of having Parkinson’s disease.
• of the subject presents with the motor symptoms of Parkinson’s disease.
• the movement disorder is presented in the subject as an adverse drug reaction to a therapeutic agent useful to treat Parkinson’s disease, such as levodopa.
• the subject is diagnosed with Parkinson’s using the Unified Parkinson’s Disease Rating Scale (UPDRS), or the Movement Disorder Society (MDS)-UPDRS.
• the subject has scored at least a 2, 3, or 4 on part three of the UPDRS or MDS-UPDRS (motor examination section).
• the subject has scored at least a 2, 3, or 4 on part 4 of the of the UPDRS or MDS-UPDRS (motor complications score).
• the subject is not diagnosed with Parkinson’s disease.
• the subject is suspected of having Parkinson’s disease but is not diagnosed with Parkinson’s disease.
• the subject is human. In some embodiments, the subject is a pediatric subject. In some embodiments, a “pediatric subject” is a human that is under about 15 years of age. In some embodiments, the subject is between 5 and 10, 6 and 11, 7 and 12, 8 and 13, 9 and 14, 10 and 15 years of age. In some embodiments, the subject is not a pediatric subject. In some embodiments, the subject is at least or about 40-45, 45-50, 50-55, 55-60, 60-65, 65-70, 70-75, or 75-80 years or age, or more. In some embodiments, the subject is a female. In some embodiments, the subject is a male.
• Parkinson ’s disease and Movement Disorders Associated with Parkinson ’s Disease are methods of treating Parkinson’s disease and movement disorders associated with Parkinson’s disease in a subject in need thereof, comprising administering a Trapidil derivative according to Formula (I) disclosed herein, or a pharmaceutically acceptable salt, co-crystal or solvate thereof, to a subject.
• the Trapidil derivatives are isotopically-labelled Trapidil derivatives.
• the isotopically-labelled Trapidil derivatives are deuterated Trapidil compounds.
• the method further comprises administering an additional therapeutic agent to the subject.
• the additional therapeutic agent is a dopamine precursor.
• the dopamine precursor is levodopa.
• the additional therapeutic agent is a dopamine agonist.
• the dopamine agonist is pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a dopamine agonist comprising pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor.
• COMP Catechol O-methyl transferase
• the COMT inhibitor is entacapone or tolcapone. In some embodiments, the COMT inhibitor is entacapone, tolcapone, or opicapone. In some embodiments, the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor comprising entacapone, tolcapone, or opicapone. In some embodiments, the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor. In some embodiments, the MAO inhibitor is selegiline or rasagiline. In some embodiments, the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor comprising selegiline or rasagiline.
• MAOB monoamine oxidase B
• the additional therapeutic agent is a dopa decarboxylase inhibitor. In some embodiments, the dopa decarboxylase inhibitor is carbidopa or benserazide. In some embodiments, the additional therapeutic agent is a dopa decarboxylase inhibitor comprising carbidopa or benserazide.
• the movement disorder associated with Parkinson’s disease is dyskinesia, akinesia, akathisia, chorea, psychomotor hyperactivity, abnormal involuntary movements, acute dyskinesia, oral dyskinesia, tongue protrusions, facial jerks, shuddering attacks, motor restlessness, motor unrest compulsive, levodopa-induced dyskinesia, dystonias, drug-induced parkinsonism, pseudo parkinsonism, bradykinesia, tremors, or any combinations thereof.
• treating Parkinson’s disease comprises treating symptoms of Parkinson’s disease.
• the symptom of Parkinson’s disease is tremors, bradykinesia, dystonias, rigidity, or any combinations thereof.
• the movement disorder associated with Parkinson’s disease is dyskinesia.
• dyskinesia is levodopa-induced dyskinesia (LID), diphasic dyskinesia, or peak-dose dyskinesia.
• dyskinesia is levodopa-induced dyskinesia (LID).
• dyskinesia is diphasic dyskinesia.
• dyskinesia is peak-dose dyskinesia.
• Dyskinesia refers to a category of movement disorders that are characterized by involuntary muscle movements, including movements similar to tics, dystonia, chorea and abnormal involuntary movements.
• Dyskinesia includes for example, from a slight tremor of the hands to an uncontrollable movement of the upper body or lower extremities.
• dyskinesia is a drug-induced dyskinesia.
• dyskinesia is a side effect of levodopa treatment.
• Dyskinesia can be a symptom of other conditions besides Parkinson’s disease.
• dyskinesia is levodopa-induced dyskinesia (LID).
• LID levodopa-induced dyskinesia refers to a form of dyskinesia associated with use of levodopa in the treatment for the motor symptoms of Parkinson’s disease. LID often involves hyperkinetic movements, including chorea, dystonia, and athetosis.
• dyskinesia is diphasic dyskinesia.
• Diphasic dyskinesia refers to a type of levodopa-induced dyskinesia that develops when plasma levodopa levels are rising or falling, but not with the peak levels. Diphasic dyskinesia primarily occurs in the lower limbs and is often dystonic or ballistic. This form of dyskinesia does not respond to reductions in the dosage of levodopa.
• dyskinesia is peak-dose dyskinesia.
• Peak-dose dyskinesia refers to a form of levodopa-induced dyskinesia that correlates with the peak plasma levels of levodopa.
• Peak-dose dyskinesia involves the head, truck, and limbs, and sometimes respiratory muscles. Peak-dose dyskinesia responds to reductions in the dosage of levodopa but at the cost of deterioration of Parkinsonism.
• methods of treating or preventing dyskinesia in a subject in need thereof comprising administering a therapeutically effective dose of a Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co-crystal or solvate thereof, to the subject.
• methods further comprise administering a therapeutically effective amount of an additional therapeutic agent (e.g., levodopa).
• methods further comprise administering a sub-therapeutically effective amount of an additional therapeutic agent (e.g., levodopa).
• the additional therapeutic agent is a dopamine precursor.
• the dopamine precursor is levodopa.
• the additional therapeutic agent is a dopamine agonist.
• the dopamine agonist is pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a dopamine agonist comprising pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor.
• COMP Catechol O-methyl transferase
• the COMT inhibitor is entacapone ortolcapone. In some embodiments, the COMT inhibitor is entacapone, tolcapone, or opicapone. In some embodiments, the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor comprising entacapone, tolcapone, or opicapone. In some embodiments, the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor. In some embodiments, the MAOB inhibitor is selegiline or rasagiline. In some embodiments, the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor comprising selegiline or rasagiline.
• MAOB monoamine oxidase B
• the additional therapeutic agent is a dopa decarboxylase inhibitor. In some embodiments, the dopa decarboxylase inhibitor is carbidopa or benserazide. In some embodiments, the additional therapeutic agent is a dopa decarboxylase inhibitor comprising carbidopa or benserazide.
• the dyskinesia is, levodopa-induced dyskinesia (LID), diphasic dyskinesia, or peak-dose dyskinesia.
• LID levodopa-induced dyskinesia
• diphasic dyskinesia diphasic dyskinesia
• peak-dose dyskinesia peak-dose dyskinesia
• methods of treating or preventing levodopa- induced dyskinesia comprising administering a therapeutically effective dose of a Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co-crystal or solvate thereof, to the subject.
• methods further comprise administering a therapeutically effective amount of an additional therapeutic agent (e.g., levodopa).
• methods further comprise administering a sub-therapeutically effective amount of an additional therapeutic agent (e.g., levodopa).
• the additional therapeutic agent is a dopamine precursor.
• the dopamine precursor is levodopa.
• the additional therapeutic agent is a dopamine agonist.
• the dopamine agonist is pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a dopamine agonist comprising pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor.
• COMP Catechol O-methyl transferase
• the COMT inhibitor is entacapone or tolcapone. In some embodiments, the COMT inhibitor is entacapone, tolcapone, or opicapone. In some embodiments, the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor comprising entacapone, tolcapone, or opicapone. In some embodiments, the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor. In some embodiments, the MAOB inhibitor is selegiline or rasagiline. In some embodiments, the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor comprising selegiline or rasagiline.
• MAOB monoamine oxidase B
• the additional therapeutic agent is a dopa decarboxylase inhibitor. In some embodiments, the dopa decarboxylase inhibitor is carbidopa or benserazide. In some embodiments, the additional therapeutic agent is a dopa decarboxylase inhibitor comprising carbidopa or benserazide.
• methods of treating or preventing diphasic dyskinesia in a subject in need thereof comprising administering a therapeutically effective dose of a Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co-crystal or solvate thereof, to the subject.
• methods further comprise administering a therapeutically effective amount of an additional therapeutic agent (e.g., levodopa).
• methods further comprise administering a sub-therapeutically effective amount of an additional therapeutic agent (e.g., levodopa).
• the additional therapeutic agent is a dopamine precursor.
• the dopamine precursor is levodopa.
• the additional therapeutic agent is a dopamine agonist.
• the dopamine agonist is pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a dopamine agonist comprising pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor.
• COMP Catechol O-methyl transferase
• the COMT inhibitor is entacapone or tolcapone. In some embodiments, the COMT inhibitor is entacapone, tolcapone, or opicapone. In some embodiments, the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor comprising entacapone, tolcapone, or opicapone. In some embodiments, the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor. In some embodiments, the MAOB inhibitor is selegiline or rasagiline. In some embodiments, the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor comprising selegiline or rasagiline.
• MAOB monoamine oxidase B
• the additional therapeutic agent is a dopa decarboxylase inhibitor. In some embodiments, the dopa decarboxylase inhibitor is carbidopa. In some embodiments, the additional therapeutic agent is a dopa decarboxylase inhibitor comprising carbidopa or benserazide.
• methods of treating or preventing peak-dose dyskinesia in a subject in need thereof comprising administering a therapeutically effective dose of a Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co-crystal or solvate thereof, to the subject.
• methods further comprise administering a therapeutically effective amount of an additional therapeutic agent (e.g., levodopa).
• methods further comprise administering a sub-therapeutically effective amount of an additional therapeutic agent (e.g., levodopa).
• the additional therapeutic agent is a dopamine precursor.
• the dopamine precursor is levodopa.
• the additional therapeutic agent is a dopamine agonist.
• the dopamine agonist is pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a dopamine agonist comprising pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor.
• COMP Catechol O-methyl transferase
• the COMT inhibitor is entacapone or tolcapone. In some embodiments, the COMT inhibitor is entacapone, tolcapone, or opicapone. In some embodiments, the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor comprising entacapone, tolcapone, or opicapone. In some embodiments, the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor. In some embodiments, the MAOB inhibitor is selegiline or rasagiline. In some embodiments, the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor comprising selegiline or rasagiline.
• MAOB monoamine oxidase B
• the additional therapeutic agent is a dopa decarboxylase inhibitor. In some embodiments, the dopa decarboxylase inhibitor is carbidopa or benserazide. In some embodiments, the additional therapeutic agent is a dopa decarboxylase inhibitor comprising carbidopa or benserazide.
• the movement disorder associated with Parkinson’s disease, or symptom of Parkinson’s disease is dystonia.
• dystonia is generalized dystonia, focal dystonia, segmental dystonia, or acute dystonia.
• dystonia is generalized dystonia.
• dystonia is focal dystonia.
• dystonia is segmental dystonia.
• dystonia is acute dystonia.
• Dystonia refers to a movement disorder in which sustained muscle contractions cause twisting and repetitive movements or abnormal postures. In some embodiments, the movements resemble tremors. Dystonia is often initiated or worsened by voluntary movements, and symptoms “overflow” into adjacent muscles. In some embodiments, dystonia is drug -induced dystonia. Dystonic reactions are characterized by intermittent spasmodic or sustained involuntary contractions of the muscles in the face, neck, trunk, pelvis, extremities, and larynx.
• dystonia is generalized dystonia.
• Generalized dystonia refers to a form of dystonia that affects most or all of the body.
• dystonia is focal dystonia.
• Focal dystonia refers to a form of dystonia that is localized to a specific part of the body.
• focal dystonia is multifocal dystonia which involves two or more unrelated body parts.
• dystonia is segmental dystonia.
• Segmental dystonia refers to a form of dystonia that affects two or more adjacent parts of the body.
• dystonia is acute dystonia.
• Acute dystonia refers to a form of dystonia consisting of sustained, often painful muscular spasms, producing twisting abnormal postures.
• methods of treating or preventing dystonia in a subject in need thereof comprising administering a therapeutically effective dose of a Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co-crystal or solvate thereof, to the subject.
• methods further comprise administering a therapeutically effective amount of an additional therapeutic agent (e.g., levodopa).
• methods further comprise administering a sub-therapeutically effective amount of an additional therapeutic agent (e.g., levodopa).
• the additional therapeutic agent is a dopamine precursor.
• the dopamine precursor is levodopa.
• the additional therapeutic agent is a dopamine agonist.
• the dopamine agonist is pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a dopamine agonist comprising pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor.
• COMP Catechol O-methyl transferase
• the COMT inhibitor is entacapone ortolcapone. In some embodiments, the COMT inhibitor is entacapone, tolcapone, or opicapone. In some embodiments, the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor comprising entacapone, tolcapone, or opicapone. In some embodiments, the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor. In some embodiments, the MAOB inhibitor is selegiline or rasagiline. In some embodiments, the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor comprising selegiline or rasagiline.
• MAOB monoamine oxidase B
• the additional therapeutic agent is a dopa decarboxylase inhibitor.
• the dopa decarboxylase inhibitor is carbidopa or benserazide.
• the additional therapeutic agent is a dopa decarboxylase inhibitor comprising carbidopa or benserazide.
• dystonia is generalized dystonia, focal dystonia, segmental dystonia, or acute dystonia.
• disclosed herein are methods of treating or preventing generalized dystonia with administration of a therapeutic effective dose of a derivative of Trapidil, or a pharmaceutically acceptable salt thereof, and/or an additional therapeutic agent (e.g., levodopa)
• methods of treating or preventing focal dystonia with administration of a therapeutic effective dose of a Trapidil derivative, or a pharmaceutically acceptable salt thereof In some embodiments, disclosed herein are methods of treating or preventing segmental dystonia with administration of a therapeutic effective dose of a Trapidil derivative, or a pharmaceutically acceptable salt thereof, and/or an additional therapeutic agent (e.g., levodopa).
• disclosed herein are methods of treating or preventing acute dystonia with administration of a therapeutic effective dose of a Trapidil derivative disclosed herein.
• the movement disorder associated with Parkinson’s disease is akathisia.
• akathisia is acute akathisia, chronic akathisia, pseudoakathisia, or withdrawal or “rebound” akathisia.
• akathisia is acute akathisia.
• akathisia is chronic akathisia.
• akathisia is pseudoakathisia.
• akathisia is withdrawal or “rebound” akathisia.
• the movement disorder is akathisia.
• akathisia is a movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion, as well as by actions such as rocking while standing or sitting, lifting the feet as if marching on the spot, and crossing and uncrossing the legs while sitting.
• akathisia is drug-induced.
• akathisia is acute akathisia.
• Acute akathisia refers to a form of akathisia that develops soon after 1) starting medication or following dose increase, 2) switching to a high-potency drug, or 3) withdrawal of a medication.
• duration of acute akathisia is less than six months and includes intense dysphoria, awareness of restlessness and complex and semi-purposeful motor fidgetiness.
• akathisia is chronic akathisia.
• Chronic akathisia refers to a form of akathisia that persists for over six months after last dosage increment of the drug.
• chronic akathisia includes mild dysphoria, awareness of restlessness, motor fidgetiness with stereotypes movement and limb and orofacial dyskinesia.
• akathisia is pseudoakathisia.
• pseudoakathisia is a late stage of chronic akathisia.
• Exemplary symptoms include motor manifestations with subjective component, motor fidgetiness with stereotyped movement and limb and orofacial dyskinesia.
• akathisia is withdrawal or “rebound” akathisia.
• withdrawal or “rebound” akathisia refers to akathisia associated with switching drugs with an onset of usually within six weeks of discontinuation or dose decrease of the drug.
• methods of treating akathisia in a subject in need thereof comprising administering a therapeutically effective dose of a Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co-crystal or solvate thereof, to the subject.
• methods further comprise administering a therapeutically effective amount of an additional therapeutic agent (e.g., levodopa).
• methods further comprise administering a sub- therapeutically effective amount of an additional therapeutic agent (e.g., levodopa).
• the additional therapeutic agent is a dopamine precursor.
• the dopamine precursor is levodopa.
• the additional therapeutic agent is a dopamine agonist.
• the dopamine agonist is pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a dopamine agonist comprising pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor.
• the COMT inhibitor is entacapone or tolcapone.
• the COMT inhibitor is entacapone, tolcapone, or opicapone.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor comprising entacapone, tolcapone, or opicapone.
• the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor.
• the MAOB inhibitor is selegiline or rasagiline.
• the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor comprising selegiline or rasagiline.
• the additional therapeutic agent is a dopa decarboxylase inhibitor.
• the dopa decarboxylase inhibitor is carbidopa or benserazide.
• the additional therapeutic agent is a dopa decarboxylase inhibitor comprising carbidopa or benserazide.
• akathisia is acute akathisia, chronic akathisia, pseudoakathisia, or withdrawal or “rebound” akathisia.
• disclosed herein are methods of treating or preventing acute akathisia with administration of a therapeutic effective dose of a Trapidil derivative disclosed herein, and/or an additional therapeutic agent (e.g., levodopa).
• a therapeutic effective dose of a Trapidil derivative disclosed herein and/or an additional therapeutic agent (e.g., levodopa).
• disclosed herein are methods of treating or preventing chronic akathisia with administration of a therapeutic effective dose of a Trapidil derivative disclosed herein, and/or an additional therapeutic agent (e.g., levodopa).
• a therapeutic effective dose of a Trapidil derivative disclosed herein and/or an additional therapeutic agent (e.g., levodopa).
• a therapeutic effective dose of a Trapidil derivative disclosed herein and/or an additional therapeutic agent (e.g., levodopa).
• an additional therapeutic agent e.g., levodopa
• a therapeutic effective dose of a Trapidil derivative disclosed herein and/or an additional therapeutic agent (e.g., levodopa).
• an additional therapeutic agent e.g., levodopa
• a method of treating Parkinson’s disease and movement disorders associated with Parkinson’s disease in a subject in need thereof comprising administering to the subject a therapeutically effective dose of a Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co-crystal or solvate thereof, to the subject.
• a therapeutically effective dose of a Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co-crystal or solvate thereof to the subject.
• methods of treating or preventing movement disorders associated with levodopa utilization are methods of treating or preventing movement disorders associated with levodopa utilization.
• a method of treating Parkinson’s disease in a subject in need thereof comprising administering to the subject a therapeutically effective dose of a Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co-crystal or solvate thereof, to the subject and an additional therapeutic agent.
• the additional therapeutic agent is an agent used for treating Parkinson’s disease.
• the additional therapeutic agent is a dopamine precursor. In some embodiments, the dopamine precursor is levodopa. In some embodiments, the additional therapeutic agent is a dopamine agonist. In some embodiments, the dopamine agonist is pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine. In some embodiments, the additional therapeutic agent is a dopamine agonist comprising pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor.
• the COMT inhibitor is entacapone or tolcapone.
• the COMT inhibitor is entacapone, tolcapone, or opicapone.
• the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor comprising entacapone, tolcapone, or opicapone.
• the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor.
• the MAOB inhibitor is selegiline or rasagiline.
• the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor comprising selegiline or rasagiline.
• MAOB monoamine oxidase B
• the additional therapeutic agent is a dopa decarboxylase inhibitor.
• the dopa decarboxylase inhibitor is carbidopa or benserazide.
• the additional therapeutic agent is a dopa decarboxylase inhibitor comprising carbidopa or benserazide.
• the additional therapeutic agent is administered orally. In some embodiments, the additional therapeutic agent is administered intravenously or subcutaneously.
• the Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co-crystal or solvate thereof, and the additional therapeutic agent are administered simultaneously. In some embodiments, the Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co-crystal or solvate thereof, and the additional therapeutic agent are administered sequentially. In some embodiments, the Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co-crystal or solvate thereof, is administered before the additional therapeutic agent.
• the Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co-crystal or solvate thereof is administered after the additional therapeutic agent.
• the Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co crystal or solvate thereof, and the additional therapeutic agent are administered in a unified dosage form.
• the Trapidil derivative according to Formula I disclosed herein, or a pharmaceutically salt, co-crystal or solvate thereof, and the additional therapeutic agent are administered in separate dosage forms.
• kits and articles of manufacture are also described herein.
• Such kits can comprise a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in a method described herein.
• Suitable containers include, for example, bottles, vials, syringes, and test tubes.
• the containers can be formed from a variety of materials such as glass or plastic.
• the container(s) can comprise a Trapidil derivative disclosed herein optionally in a composition or in combination with another agent as disclosed herein (e.g., levodopa and/or carbidopa).
• the container(s) optionally have a sterile access port (for example the container can be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
• kits optionally comprise a compound with an identifying description or label or instructions relating to its use in the methods described herein.
• a kit will typically comprise one or more additional containers, each with one or more of various materials (such as reagents, optionally in concentrated form, and/or devices) desirable from a commercial and user standpoint for use of a Trapidil derivative disclosed herein.
• materials include, but are not limited to, buffers, diluents, fdters, needles, syringes; carrier, package, container, vial and/or tube labels listing contents and/or instructions for use, and package inserts with instructions for use.
• a set of instructions will also typically be included.
• a label can be on or associated with the container.
• a label can be on a container when letters, numbers or other characters forming the label are attached, molded or etched into the container itself; a label can be associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert.
• a label can be used to indicate that the contents are to be used for a specific therapeutic application.
• the label can also indicate directions for use of the contents, such as in the methods described herein.
• These other therapeutic agents may be used, for example, in the amounts indicated in the Physicians’ Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.
• subject refers to any animal, preferably a mammal, including a human or non human.
• subject and patient are used interchangeably herein in reference, for example, to a mammalian subject, such as a human subject. None of the terms are to be interpreted as requiring the supervision of a medical professional (e.g., a doctor, nurse, physician’s assistant, orderly, hospice worker).
• a medical professional e.g., a doctor, nurse, physician’s assistant, orderly, hospice worker.
• the terms “treat,” “treating,” and “treatment” are meant to include alleviating or abrogating a movement disorder, disease, or condition; or one or more of the symptoms associated with the movement disorder, disease, or condition; or alleviating or eradicating the cause(s) of the disorder, disease, or condition itself.
• the terms “prevent,” “preventing,” and “prevention” refer to a method of delaying or precluding the onset of Parkinson’s disease or a movement disorder associated with Parkinson’s disease; and/or its attendant symptoms, barring a subject from acquiring a disease or reducing a subject’s risk of acquiring Parkinson’s disease or a movement disorder associated with Parkinson’s disease.
• terapéuticaally effective amount refers to the amount of a Trapidil derivative disclosed herein that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the Parkinson’s disease or movement disorder associated with Parkinson’s disease.
• therapeutically effective amount also refers to the amount of a Trapidil derivative disclosed herein that is sufficient to elicit the biological or medical response of a cell, tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor, or clinician.
• sub-therapeutically effective amount refers to the amount of a therapeutic agent that is below a dosage amount that is considered therapeutically effective for the treatment of an intended indication.
• the therapeutic agent is levodopa.
• pharmaceutically acceptable carrier refers to a pharmaceutically- acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material.
• pharmaceutically- acceptable material such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material.
• Each component must be “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a pharmaceutical formulation. It must also be suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit/risk ratio.
• composition refers to a mixture of a compound disclosed herein with other chemical components, such as diluents or carriers.
• deuterium enrichment refers to the percentage of incorporation of deuterium at a given position in a molecule in the place of hydrogen. For example, deuterium enrichment of about 1% at a given position means that about 1% of molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156%, deuterium enrichment at any positions in a compound synthesized using non-enriched starting materials is about 0.0156%. The deuterium enrichment can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.
• isotopic enrichment refers to the percentage of incorporation of a less prevalent isotope of an element at a given position in a molecule in the place of the more prevalent isotope of the element.
• non-isotopically enriched refers to a molecule in which the percentages of the various isotopes are substantially the same as the naturally occurring percentages.
• active ingredient refers to a compound, which is administered, alone or in combination with one or more pharmaceutically acceptable excipients, to a subject for treating, preventing, or ameliorating one or more symptoms of a disorder or disease.
• a subject diagnosed with a movement disorder associated with Parkinson’s disease is administered a therapeutically effective amount of a Trapidil derivative according to Formula I, or a pharmaceutically salt, co-crystal or solvate thereof, and levodopa, thereby treating or preventing the movement disorder in the subject.
• Example 3-1, 3-2, and 3-3 were characterized by 3 ⁇ 4 and 13 C NMR and GCMS, the results of which are shown in Table A below.
• Example 3-1 (“3-1”) has 4 deuterium atoms on the diethylamino chain
• Example 3-2 (“3-2”) has 6 deuterium atoms
• Example 3-3 (“3-3”) has 10 deuterium atoms in total (combining the 4 deuterium atoms from 3-1 and the 6 deuterium atoms from 3-2).
• Example 3-1 Example 3-2
• Example 3-3 Example 3-3
• Example 3-4 Example 3-5
• Example 3-6 Example 3-6
• Example 4 Pharmacokinetic Properties of Examples 3-1 to 3-3 Compared with Trapidil
• deuterated Trapidil derivatives exhibited superior PK profiles as compared to unmodified Trapidil.
• the inventors of the present disclosure discovered that certain deuterated Trapidil derivatives with fewer deuterium exhibited superior PK profiles as compared with comparable deuterated Trapidil derivatives with more deuterium.
• FIG. 1 shows the results from this experiment on a linear scale. All Trapidil deuterated derivatives showed increased plasma concentrations at Cmax compared with Trapidil.
• FIG. 2 shows the same results on a logarithmic scale.
• 3-1 shows a decreased slope (versus the other three compounds) indicating the 3-1 is metabolized in rats at a slower rate than 3-2, 3-3, and Trapidil when administered orally. The rank order of the rates of metabolism was unexpected.
• PK properties of Trapidil and the Trapidil Derivatives Tested for Oral Administration “NS” means “not significant”; “*” means “p ⁇ 0.05 compared to 3-2”; “@” means “p ⁇ 0.05 compared to 3-3.”
• FIG. 3 shows the results from this experiment on a linear scale and Fig. 4 shows the same results on a logarithmic scale.
• Table 2B all Trapidil derivatives exhibited longer half-lives as compared with Trapidil, with 3-1 exhibiting the longest half-life, similar to the oral administration results. Further, Cmax was increased for 3-1 and 3-2 but not 3-3. This was an unexpected result.
• PK properties of Trapidil and the Trapidil Derivatives Tested for Intravenous Administration “NS” means “not significant”; “*” means “p ⁇ 0.05 compared to 3-2”; “@” means “p ⁇ 0.05 compared to 3- 3.”
• Bioavailability of Trapidil and the Trapidil derivatives 3-1, 3-2, and 3-3 was calculated. Bioavailability is the ratio of how much of the drug reaches systemic circulation from oral administration. It was calculated by comparing the AUC of the oral administration (PO) to the administration directly into the bloodstream (IV).
• Tables 4 and 5 show the half-life of compounds 3-1 to 3-9 relative to trapidil for rat and human liver microsomes respectively. Rat microsome results are similar to those seen in rodents in vivo (Example 4) with a significant increase in half-life for compound 3-1. Increased half-life in human liver microsomes (Table 5) provides evidence for translation of pharmacokinetic results in humans.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Psychology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Steroid Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (12)

Applications Claiming Priority (4)

Related Child Applications (1)

Publications (1)

Family

ID=77892379

Family Applications (1)

Country Status (10)

Cited By (1)

Families Citing this family (1)

Citations (3)

Family Cites Families (55)

• 2021
  • 2021-03-25 MX MX2022011879A patent/MX2022011879A/es unknown
  • 2021-03-25 IL IL296788A patent/IL296788A/en unknown
  • 2021-03-25 AU AU2021244241A patent/AU2021244241A1/en active Pending
  • 2021-03-25 CA CA3177066A patent/CA3177066A1/en active Pending
  • 2021-03-25 CN CN202310374367.9A patent/CN116496279B/zh active Active
  • 2021-03-25 JP JP2022558003A patent/JP7730336B2/ja active Active
  • 2021-03-25 CN CN202511776120.5A patent/CN121550230A/zh active Pending
  • 2021-03-25 KR KR1020227037235A patent/KR20230013023A/ko active Pending
  • 2021-03-25 EP EP21774988.6A patent/EP4125853A4/en active Pending
  • 2021-03-25 WO PCT/US2021/024226 patent/WO2021195425A1/en not_active Ceased
  • 2021-03-25 CN CN202180038452.7A patent/CN115916180A/zh active Pending
• 2022
  • 2022-09-23 US US17/934,680 patent/US12508267B2/en active Active
• 2025
  • 2025-08-14 JP JP2025135217A patent/JP2025183224A/ja active Pending

Patent Citations (3)

Non-Patent Citations (11)

Also Published As

Similar Documents

Legal Events